1. Introduction {#sec1-medicina-55-00041}
===============

Lung cancer is the second most common malignancy in both genders worldwide \[[@B1-medicina-55-00041]\]. It still remains the leading cause of cancer-associated deaths \[[@B1-medicina-55-00041],[@B2-medicina-55-00041]\], although systemic chemotherapy or immune checkpoint inhibitors can significantly improve prognosis for patients with advanced non-small-cell lung cancer (NSCLC) \[[@B3-medicina-55-00041],[@B4-medicina-55-00041],[@B5-medicina-55-00041]\]. For patients with epidermal growth factor receptor (*EGFR*)-mutant NSCLC, targeted therapy with tyrosine kinase inhibitors (TKIs) can significantly prolong survival \[[@B6-medicina-55-00041],[@B7-medicina-55-00041]\].

Thyroid transcription factor-1 (TTF-1) is a regulatory transcription factor for tissue-specific genes \[[@B8-medicina-55-00041]\]. It is expressed in the thyroid, forebrain, or lungs, playing a physiologic role during their development. In the normal lungs, TTF-1 helps to maintain functions of terminal respiratory unit cells \[[@B9-medicina-55-00041]\]. High TTF-1 expression by immunohistochemistry (IHC) has been observed in 70--90% of primary lung adenocarcinomas (ADCs), while almost all squamous cell carcinomas are negative for TTF-1 IHC. Therefore, it has been considered a specific marker of ADCs of the lung. In addition, TTF-1 overexpression is a favorable prognostic factor not only in early-stage but also in advanced non-squamous NSCLC \[[@B10-medicina-55-00041],[@B11-medicina-55-00041]\].

EGFR is a member of the hermaphrodite (HER) family of tyrosine kinase receptors, and somatic activating mutations in the adenosine triphosphate (ATP)-binding site of EGFR result in a more effective binding of EGFR TKIs \[[@B12-medicina-55-00041],[@B13-medicina-55-00041]\]. *EGFR* gene mutations in four kinase domains (exons 18--21) comprise in-frame deletions, in-frame insertions/duplications, and point mutations \[[@B14-medicina-55-00041],[@B15-medicina-55-00041]\]. NSCLC patients with *EGFR* mutations can achieve better progression-free survival and overall survival when treated with an EGFR TKI as first-line treatment rather than chemotherapy \[[@B6-medicina-55-00041],[@B16-medicina-55-00041],[@B17-medicina-55-00041],[@B18-medicina-55-00041]\]. Therefore, it is essential to determine the *EGFR* mutation status of patients with advanced NSCLC when planning anticancer therapy.

However, for some patients, it is not easy to determine the *EGFR* mutation status because of inadequate tumor specimen or expense. Therefore, the identification of other pathologic markers that can predict *EGFR* mutation status may be very useful in clinical practice. In NSCLC, both TTF-1 expression and *EGFR* mutations are closely related to the female gender, non-smoking status, and ADC \[[@B13-medicina-55-00041],[@B19-medicina-55-00041],[@B20-medicina-55-00041],[@B21-medicina-55-00041],[@B22-medicina-55-00041]\]. In addition, some studies suggested that TTF-1 expression had a significant positive correlation with *EGFR* mutations \[[@B21-medicina-55-00041],[@B22-medicina-55-00041]\]. This meta-analysis assessed the relationship between TTF-1 expression and *EGFR* mutations in NSCLC to clarify whether TTF-1 can be a potential predictive biomarker for *EGFR* mutation status in patients with NSLCL.

2. Materials and Methods {#sec2-medicina-55-00041}
========================

2.1. Publication Search Strategy {#sec2dot1-medicina-55-00041}
--------------------------------

This meta-analysis was done according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@B23-medicina-55-00041]\]. A systematic search of the databases including PubMed, EMBASE, Cochrane Library, and Google Scholar (up to December 2018) was performed to identify studies assessing the correlation of TTF-1 expression with *EGFR* mutations. The search used a combination of the following terms: "epidermal growth factor receptor" or "EGFR" AND "mutation" AND "thyroid transcription factor-1" or "TTF-1" AND "non-small-cell lung cancer" or "NSCLC" or "lung cancer." All of the relevant articles identified by the related article function were also included in the analysis. The references reported in the identified articles were also reviewed to complete the search process.

2.2. Eligibility Criteria {#sec2dot2-medicina-55-00041}
-------------------------

Eligible studies should meet the following inclusion criteria: (i) patients with pathologically confirmed NSCLC; (ii) analysis of *EGFR* mutations in exons 19 and 21; (iii) IHC test for TTF-1 expression in lung cancer tissue; (iv) the use of adequate IHC methods and criteria for positive TTF-1 staining; and (v) prospective or retrospective cohort studies assessing the correlation of TTF-1 expression with *EGFR* mutations.

2.3. Article Review and Data Extraction {#sec2dot3-medicina-55-00041}
---------------------------------------

Two authors (D.R.C. and B.H.) independently searched the databases and extracted data from the selected studies. The following data were extracted from each study: the first author, year of publication, study design, inclusion period, country, sample size, histology, disease stage, TTF-1 expression status, IHC criteria for positive expression, *EGFR* mutation status, and detecting method.

2.4. Quality Assessment {#sec2dot4-medicina-55-00041}
-----------------------

The methodological quality of included studies was scored based on the Newcastle--Ottawa System (NOS) with the score range of zero to nine \[[@B24-medicina-55-00041]\]. Studies having a score ≥ six were considered to have a high quality.

2.5. Statistical Analysis {#sec2dot5-medicina-55-00041}
-------------------------

The strength of the association between TTF-1 expression and *EGFR* mutations was shown as odds ratios (ORs) with 95% confidence intervals (CIs). If the study did not report the OR or 95% CI directly, we calculated them from available data by using the Engauge Digitizer software. The heterogeneity of the individual ORs was estimated using the chi-squared test with significance being set at *p \<* 0.1. The total variation among studies was estimated by anI^2^ inconsistency test, where I^2^ \> 50% was considered to indicate significant heterogeneity. If there was heterogeneity among studies, we used the random effect model based on the DerSimonian--Laird method to pool the OR. Otherwise (*p* ≥ 0.1 and I^2^ ≤ 50%), the fixed effect model based on the Mantel--Haenszel method was selected. Subgroup analyses were planned according to the ethnicity and mutational types. The sensitivity analysis was performed to detect the influence of individual trials on the pooled results by removing one trial each time. Forest plots were produced to show a summary estimate of the combined results of all the studies. Each square represented the OR point estimate, and its size was proportional to the weight of the study. The location of the diamond represented the estimated effect size, and its width reflected the precision of the estimate.

The potential publication bias was assessed by visual inspection of the funnel plot \[[@B25-medicina-55-00041]\]. For quantitative analyses, Egger's test and Begg's tests were performed using the statistical software packages R \[[@B26-medicina-55-00041]\]. Statistical significances were considered when a *p*-value was less than 0.05.

3. Results {#sec3-medicina-55-00041}
==========

3.1. Search Results {#sec3dot1-medicina-55-00041}
-------------------

The search process identified 114 potentially relevant articles; however, 74 articles were excluded by screening of the titles and abstracts. Of the remaining 40 studies, 25 articles that failed to meet the inclusion criteria were further excluded. We manually searched the reference lists of the selected articles and found two more relevant articles. Eventually, a total of 17 studies were included in the meta-analysis \[[@B21-medicina-55-00041],[@B27-medicina-55-00041],[@B28-medicina-55-00041],[@B29-medicina-55-00041],[@B30-medicina-55-00041],[@B31-medicina-55-00041],[@B32-medicina-55-00041],[@B33-medicina-55-00041],[@B34-medicina-55-00041],[@B35-medicina-55-00041],[@B36-medicina-55-00041],[@B37-medicina-55-00041],[@B38-medicina-55-00041],[@B39-medicina-55-00041],[@B40-medicina-55-00041],[@B41-medicina-55-00041],[@B42-medicina-55-00041]\] ([Figure 1](#medicina-55-00041-f001){ref-type="fig"}).

3.2. Characteristics of the Included Studies {#sec3dot2-medicina-55-00041}
--------------------------------------------

The main characteristics of the studies selected for this meta-analysis are summarized in [Table 1](#medicina-55-00041-t001){ref-type="table"}. Except for two studies without any description about study design \[[@B35-medicina-55-00041],[@B40-medicina-55-00041]\], seven recruited patients prospectively \[[@B21-medicina-55-00041],[@B27-medicina-55-00041],[@B30-medicina-55-00041],[@B32-medicina-55-00041],[@B34-medicina-55-00041],[@B39-medicina-55-00041],[@B41-medicina-55-00041]\], and the remaining studies were performed retrospectively \[[@B28-medicina-55-00041],[@B29-medicina-55-00041],[@B31-medicina-55-00041],[@B33-medicina-55-00041],[@B36-medicina-55-00041],[@B37-medicina-55-00041],[@B38-medicina-55-00041],[@B42-medicina-55-00041]\]. The NOS scores were more than seven in all of the included studies, suggesting a good methodological quality.

The criteria for the positivity of TTF-1 expression in IHC staining varied across studies; however, the rates of TTF-1 expression in most of the included studies were 80--90%. Six studies contained NSCLC \[[@B28-medicina-55-00041],[@B29-medicina-55-00041],[@B31-medicina-55-00041],[@B32-medicina-55-00041],[@B36-medicina-55-00041],[@B41-medicina-55-00041]\], and 10 studies only included ADC \[[@B21-medicina-55-00041],[@B27-medicina-55-00041],[@B30-medicina-55-00041],[@B33-medicina-55-00041],[@B34-medicina-55-00041],[@B35-medicina-55-00041],[@B38-medicina-55-00041],[@B39-medicina-55-00041],[@B40-medicina-55-00041],[@B42-medicina-55-00041]\]. Two studies included patients with stages I--III ADC \[[@B21-medicina-55-00041],[@B38-medicina-55-00041]\], and five were conducted in patients with advanced disease (stages III--IV) \[[@B30-medicina-55-00041],[@B32-medicina-55-00041],[@B36-medicina-55-00041],[@B37-medicina-55-00041],[@B42-medicina-55-00041]\].

The *EGFR* mutations were usually detected by polymerase chain reaction (PCR) and direct DNA sequencing methods, or by amplification refractory mutation system (ARMS) analysis. Most of the studies examined four kinase domains in exons 18--21; however, some screened for *EGFR* mutations in only exons 19 and 21 \[[@B21-medicina-55-00041],[@B31-medicina-55-00041],[@B36-medicina-55-00041]\].

3.3. Correlation of TTF-1 Expression and EGFR Mutations {#sec3dot3-medicina-55-00041}
-------------------------------------------------------

### 3.3.1. Overall {#sec3dot3dot1-medicina-55-00041}

A total of 9764 patients from the 17 studies were included in the meta-analysis to determine the association of TTF-1 expression and *EGFR* mutations \[[@B21-medicina-55-00041],[@B27-medicina-55-00041],[@B28-medicina-55-00041],[@B29-medicina-55-00041],[@B30-medicina-55-00041],[@B31-medicina-55-00041],[@B32-medicina-55-00041],[@B33-medicina-55-00041],[@B34-medicina-55-00041],[@B35-medicina-55-00041],[@B36-medicina-55-00041],[@B37-medicina-55-00041],[@B38-medicina-55-00041],[@B39-medicina-55-00041],[@B40-medicina-55-00041],[@B41-medicina-55-00041],[@B42-medicina-55-00041]\]. The combined OR of 5.19 (95% CI: 3.60--7.47, *p* \< 0.00001, random-effects model, [Figure 2](#medicina-55-00041-f002){ref-type="fig"}) indicated that NSCLCs with TTF-1 overexpression exhibited significantly higher rate of *EGFR* mutations. There was a significant heterogeneity among studies (X^2^ = 54.26, *p* \< 0.00001, I^2^ = 71%).

### 3.3.2. Subgroup Analysis According to the Ethnic Group {#sec3dot3dot2-medicina-55-00041}

When we performed the subgroup analysis according to the region, the combined ORs were 4.33 (95% CI: 3.46--5.41, *p* \< 0.00001, fixed-effects model) for patients in East Asia ([Figure 3](#medicina-55-00041-f003){ref-type="fig"}A) and 4.64 (95% CI: 1.41--15.28, *p* \< 0.01, random-effects model) for patients in Europe ([Figure 3](#medicina-55-00041-f003){ref-type="fig"}B).

### 3.3.3. Subgroup Analysis According to the Gender {#sec3dot3dot3-medicina-55-00041}

The subgroup analysis using data from three studies \[[@B30-medicina-55-00041],[@B34-medicina-55-00041],[@B38-medicina-55-00041]\] indicated there was a significant correlation between TTF-1 expression and *EGFR* mutations in both female (OR = 4.87, 95%CI 2.27--10.45, fixed-effect model, [Figure 4](#medicina-55-00041-f004){ref-type="fig"}A, *p* \< 0.0001) and male patients (OR = 3.34, 95%CI 1.43--6.82, fixed-effect model, [Figure 4](#medicina-55-00041-f004){ref-type="fig"}B, *p* = 0.0009).

### 3.3.4. Subgroup Analysis According to the Mutational Subtype {#sec3dot3dot4-medicina-55-00041}

The pooled data from four studies \[[@B30-medicina-55-00041],[@B34-medicina-55-00041],[@B38-medicina-55-00041],[@B41-medicina-55-00041]\] revealed a significant correlation between TTF-1 expression and *EGFR* mutations in both exon 19 (OR = 4.63, 95% CI: 2.89--7.41, *p* \< 0.00001, fixed-effect model, [Figure 5](#medicina-55-00041-f005){ref-type="fig"}A) and exon 21 (OR = 3.16, 95% CI: 1.04--9.60, *p* = 0.04, random-effects model, [Figure 5](#medicina-55-00041-f005){ref-type="fig"}B).

3.4. Publication Bias {#sec3dot4-medicina-55-00041}
---------------------

Visual inspection of the funnel plot for ORs showed symmetry, indicating that there was no substantial publication bias ([Figure 6](#medicina-55-00041-f006){ref-type="fig"}). Egger's and Begg's tests also indicated no evidence of substantial publication bias, with *p*-values of 0.172 and 0.152, respectively.

4. Discussion {#sec4-medicina-55-00041}
=============

Over the past two decades, several major progresses have been made toward the personalized treatment for patients with NSCLC. The first breakthrough was the discovery of *EGFR* mutations. TKIs are small molecular agents targeting *EGFR* mutations that have revolutionized the treatment of NSCLC, leading to improved survival in patients with advanced or metastatic *EGFR*-mutant tumor \[[@B6-medicina-55-00041],[@B7-medicina-55-00041]\]. Therefore, it is essential to screen for *EGFR* mutations before introducing anticancer treatment for patients with advanced NSCLC.

Studies evaluating the prognostic value of TTF-1 expression in NSCLC reported TTF-1 expression to be an independent predictor of survival \[[@B10-medicina-55-00041],[@B11-medicina-55-00041],[@B43-medicina-55-00041],[@B44-medicina-55-00041]\]. In the North East Japan 002 study, investigators reported that the rate of *EGFR* mutations was higher in patients with ADC positive for TTF-1 expression \[[@B6-medicina-55-00041]\]. In particular, Asians, women, and non-smokers revealed a higher rate of *EGFR* mutations and TTF-1 positive expression. Based on these findings, some researchers hypothesized that TTF-1 expression is significantly correlated with *EGFR* mutations in patients with lung ADC \[[@B34-medicina-55-00041]\].

In the current meta-analysis, we combined the data from 17 studies, including 9764 patients, to determine whether positive TTF-1 expression by IHC can be a surrogate marker for *EGFR* mutation status in NSCLC. The results revealed that *EGFR* mutations were significantly correlated with TTF-1 overexpression in patients with NSCLC (OR = 5.34, 95% CI: 3.54--8.04, *p* \< 0.00001). Both high TTF-1 expression and *EGFR* mutations have been known to be significantly associated with Asian, women, and non-smokers. However, our subgroup analysis according to the ethnicity indicated that the correlation of TTF-1 expression and *EGFR* mutations was observed in European patients (OR = 4.64, 95% CI: 1.41--15.28, *p* \< 0.01) as well as East Asian (OR = 4.33, 95% CI: 3.46--5.41, *p* \< 0.00001). In addition, in the subgroup analysis according to the gender, the significant correlation between TTF-1 expression and *EGFR* mutations was observed not only in female (OR = 4.87, 95% CI 2.27--10.45, *p* \< 0.0001), but also in male patients with NSCLC (OR = 3.34, 95% CI 1.43--6.82, *p* = 0.0009).

Among *EGFR* mutations, deletion in exon 19 and L858R mutation in exon 21 are common, accounting for more than 90% of all *EGFR* mutations. Some studies conducted subgroup analysis according to *EGFR* mutation subtype and reported that positive TTF-1 expression was only significantly correlated with *EGFR* mutation in exon 21, and not on exon 19 \[[@B34-medicina-55-00041],[@B38-medicina-55-00041]\]. However, Zhao et al. also observed a significant correlation of TTF-1 positivity with *EGFR* mutation in exon 21 in Chinese patients with lung ADC \[[@B38-medicina-55-00041]\]. In the current meta-analysis, the pooled data from four studies \[[@B30-medicina-55-00041],[@B34-medicina-55-00041],[@B38-medicina-55-00041],[@B41-medicina-55-00041]\] indicated a significant relationship between TTF-1 expression and *EGFR* mutation in both exon 19 (OR = 4.63, 95% CI: 2.89--7.41, *p* \< 0.00001) and exon 21 (OR = 3.16, 95% CI: 1.04--9.60, *p* = 0.04).

Several studies reported a high negative predictive value (88.2--97%) of TTF-1 for the presence of activating *EGFR* gene mutations \[[@B21-medicina-55-00041],[@B28-medicina-55-00041],[@B35-medicina-55-00041],[@B40-medicina-55-00041]\]. In this study, only 9.8% (176 of 1801) of TTF-1--negative NSCLC cases had *EGFR* mutations. Overall, the negative predictive value of TTF-1 for *EGFR* mutations was 90.2%. However, when including only patients in Europe, where the rate of *EGFR* mutations is low, the negative predictive value of TTF-1 increased to 96.2%. Therefore, when the status of *EGFR* mutations cannot be tested in a timely manner because of inadequate tumor tissue or when treatment for NSCLC is urgent for clinical reasons, the IHC staining result of TTF-1 may be used to guide systemic anticancer therapy. In particular, negative TTF-1 expression can be a surrogate marker to recommend conventional chemotherapy.

This study has several limitations. First, the included studies showed considerable diversity in the methods used for TTF-1 staining and *EGFR* mutation detection. In addition, the cut-off criteria for positive TTF-1 staining also varied among studies. Second, the rate of TTF-1 overexpression and *EGFR* mutations are significantly higher with NSCLC patients with no smoking history. However, we could not perform a subgroup analysis according to the smoking status because of the limited data. Third, the substantial heterogeneity observed among studies could not be interpreted thoroughly, even though the random-effects model was selected. Finally, about half of the included studies were retrospective and therefore may carry the biases inherent to the study design.

5. Conclusions {#sec5-medicina-55-00041}
==============

This meta-analysis indicates a significant correlation between TTF-1 overexpression and *EGFR* mutations status in patients with NSCLC. In clinical practice, the status of TTF-1 expression may be a biomarker to guide anticancer therapy in advanced NSCLC patients with unknown *EGFR* mutation status. Especially, negative TTF-1 expression has such a high negative predictive value for *EGFR* mutations that it might be a surrogate marker to recommend conventional chemotherapy first when the status of *EGFR* mutations cannot be tested in a timely manner.

J.H.K. designed the study. B.H. and D.R.C. searched the literatures and extracted the data. H.S.K. performed the statistical analyses. H.S.K. and J.H.K. wrote the manuscript.
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medicina-55-00041-t001_Table 1

###### 

Summary of the 17 included studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First Author (Year) \[Ref.\]                    Country       Design   Sample Size   Inclusion Period   Pathology   Tumor Stage      IHC Criteria for TTF-1 (+): Nuclear Staining    Test for EGFR Mutations   TTF-1 Expression     *EGFR* MT\      Significance     NOS Score
                                                                                                                                                                                                                                      a/t TTF-1 (%)                    
  ----------------------------------------------- ------------- -------- ------------- ------------------ ----------- ---------------- ----------------------------------------------- ------------------------- -------------------- --------------- ---------------- -----------
  Hiramatsu (2010) \[[@B27-medicina-55-00041]\]   Japan         Pro      93            1998--2001         ADC         I--IV            Stronger than xenograft staining                PCR                       (+): 74 (79.6%)\     48 (64.9%)\     *p* = 0.017      6
                                                                                                                                                                                                                 (−): 19 (20.4%)      6 (31.6%)                        

  Vincenten (2012) \[[@B28-medicina-55-00041]\]   Netherlands   Retro    745           2004--2010         NSCLC       I--IV            Percentage (0--100%) × intensity (0--3) ≥10     PCR sequencing            (+): 508 (68.2%)\    105 (20.7%)\    *p* \< 0.00001   8
                                                                                                                                                                                                                 (−): 237 (31.8%)     9 (3.8%)                         

  Sun (2012) \[[@B29-medicina-55-00041]\]         Korea         Retro    190           2006--2010         NSCLC       NA               Percentage (0--100%) × intensity (0--3) \>100   PCR sequencing            (+): 151 (79.4%)\    77 (60.0%)\     *p* \< 0.001     8
                                                                                                                                                                                                                 (−): 39 (20.6%)      6 (15.4%)                        

  Chung (2012) \[[@B30-medicina-55-00041]\]       Taiwan        Pro      496           2004--2009         ADC         IIIB--IV         Any definite nuclear staining                   PCR sequencing            (+): 443 (89.3%)\    274 (61.9%)\    *p* \< 0.001     8
                                                                                                                                                                                                                 (−): 53 (10.7%)      17 (32.1%)                       

  Vallee (2013) \[[@B31-medicina-55-00041]\]      France        Retro    1038          2010--2012         NSCLC       I--IV            NA                                              PCR                       (+): 820 (79.0%)\    145 (17.7%)\    *p* \< 0.0001    8
                                                                                                                                                                                                                 (−): 218 (21.0%      3 (1.4%)                         

  Gahr (2013) \[[@B32-medicina-55-00041]\]        Germany       Pro      854           2010               NSCLC       Mainly IV        NA                                              Sanger sequencing         (+): 627 (73.4%)\    101 (16.1%)\    *p* \< 0.001     8
                                                                                                                                                                                                                 (−): 227 (26.6%)     7 (3.1%)                         

  Liu (2014) \[[@B21-medicina-55-00041]\]         China         Pro      139           2008--2011         ADC         I--III           Intensity (0--3) x reactivity (0--100) \> 100   ARMS PCR                  (+): 122 (87.8%)\    63 (51.6%)\     *p* = 0.002      7
                                                                                                                                                                                                                 (−): 17 (12.2%)      2 (11.8%)                        

  Warth (2014) \[[@B33-medicina-55-00041]\]       Germany       Retro    418           2002--2008         ADC         I--IV            NA                                              Sanger sequencing         (+): 366 (87.6%)\    56 (15.3%)\     *p* = 0.685      8
                                                                                                                                                                                                                 (−): 52 (12.4%)      9 (17.3%)                        

  Shanzhi (2014) \[[@B34-medicina-55-00041]\]     China         Pro      664           2010--2013         ADC         I--IV            \>10% of tumor cells                            PCR sequencing            (+): 654 (98.5%)\    261 (39.9%)\    *p* \< 0.001     8
                                                                                                                                                                                                                 (−): 10 (1.5%)       1 (10%)                          

  Somaiah (2014) \[[@B35-medicina-55-00041]\]     USA           NA       431           NA                 ADC         NA               NA                                              Allele-specific PCR       (+): 366 (84.9%)\    242 (66.1%)\    *p* \< 0.00001   8
                                                                                                                                                                                                                 (−): 66 (15.3%)      3 (4.5%)                         

  Shiau (2014) \[[@B36-medicina-55-00041]\]       Canada        Retro    1736          2010--2012         Non-SQCC    Mainly III--IV   NA                                              PCR                       (+): 1408 (81.1)\    327 (23.2)\     *p* \< 0.00001   8
                                                                                                                                                                                                                 (−): 328 (18.9)      21 (6.4)                         

  Elsamany (2015) \[[@B37-medicina-55-00041]\]    Egypt         Retro    80            2011--2012         Non-SQCC    IIIB--IV         NA                                              NA                        (+): 70 ((87.5%)\    20 (28.6%)\     *p* = 0.28       6
                                                                                                                                                                                                                 (−): 10 (12.5%)      1 (10%)                          

  Zhao (2015) \[[@B38-medicina-55-00041]\]        Taiwan        Retro    200           2008--2013         ADC         I--IV            ≥ 10% of tumor cells                            EGFR liquid chip          (+): 163 (81.5%)\    83 (50.9%)\     *p* = 0.000      7
                                                                                                                                                                                                                 (−): 37 (18.5%)      6 (16.2%)                        

  Zhang (2015) \[[@B39-medicina-55-00041]\]       China         Pro      1042          2008--2013         ADC         I--III           Any positive nuclear staining                   PCR                       (+): 909 (87.26%)\   552 (60.7%)\    *p* \< 0.001     8
                                                                                                                                                                                                                 (−): 133 (12.8%)     50 (37.6%)                       

  Udupa\                                          India         NA       85            2009-2013          ADC         I--IV            NA                                              ARMS real-time PCR        (+): 68 (80%)\       33 (48.5%)\     *p* \< 0.00001   6
  (2015) \[[@B40-medicina-55-00041]\]                                                                                                                                                                            (−): 17 (20%)        1 (5.9%)                         

  Wei (2016) \[[@B41-medicina-55-00041]\]         China         Pro      1083          2010--2016         NSCLC       I--IV            Tan or brown nuclear staining                   ARMS PCR                  (+): 841 (77.7%)\    385 (45.8%)\    *p* \< 0.001     8
                                                                                                                                                                                                                 (−): 242 (22.3%)     28 (11.6%)                       

  Schilsky (2017) \[[@B42-medicina-55-00041]\]    USA           Retro    479           2009--2011         ADC         IV               Any nuclear reactivity                          NA                        (+): 383 (80.0%)\    92 (24.0%)\     *p* \< 0.001     8
                                                                                                                                                                                                                 (−): 96 (20.0%)      6 (6.3%)                         
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EGFR, epidermal growth factor receptor; NOS, Newcastle--Ottawa System; NSCLC, non-small-cell lung cancer; Pro, prospective; Retro, retrospective; pts, Patients; ADC, adenocarcinoma; SQCC, squamous cell carcinoma; TTF-1, thyroid transcription factor 1; ARMS, amplification refractory mutation system; PCR, polymerase chain reaction; IHC, immunohistochemistry; a/t, according to; NA, not available.
